Report From the 2022 Mary Tyler Moore Vision Initiative Diabetic Retinal Disease Clinical Endpoints Workshop.

The Mary Tyler Moore Vision Initiative Diabetic Retinal Disease (DRD) Clinical Endpoints Workshop was held on October 22, 2022 to accelerate progress toward establishment of useful clinical and research endpoints and development of new therapeutics that have important relevance across the full spectrum of DRD pathology. More than 90 patient representatives, clinicians, scientists, funding and regulatory agencies, diagnostic, therapeutic and biotech industry representatives discussed the needs for new diagnostic and therapeutic approaches to prevent and restore retinal neurovascular unit integrity. Phase I of the MTM Vision Initiative plans, notably updating the DRD staging system and severity scale, establishing a human ocular biorepository and resource, and clinical endpoints and biomarker development and validation, was emphasized.

Scaling laws of plume-induced granular cratering.

Extraterrestrial landing often requires firing a high-speed plume towards a planetary surface, and the resulting gas-granular interactions pose potential hazards to the lander. To investigate these jet-induced cratering dynamics, an experiment campaign covering a range of gas and granular properties relevant to the lunar and Martian environments was conducted in a large-scale vacuum chamber. Despite the variations in jet Mach number, mass flow rate, and composition of the granular phase investigated in this work, the observed time evolution of crater depth displays a consistent transition from an early-stage linear to a late-stage sublinear growth.

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.

On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. The FDA granted approval based on the clinically meaningful effects on overall response rate (ORR) observed in patients enrolled in Study MK-6482-004. All 61 patients had VHL-associated RCC; some also had CNS hemangioblastomas and/or pNET.

Association of Daratumumab Use With Ocular Events in a Case Series of US Adults.

This case series uses postmarketing data to evaluate the association of daratumumab use with ocular events such as acute angle-closure glaucoma, myopic shift, and choroidal effusions among US adults.